Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals

a nationwide cohort study

L H Omland, N Weis, P Skinhøj, Alex Laursen, Peer Brehm Christensen, H I Nielsen, Axel Møller, F Engsig, Henrik Toft Sørensen, N Obel

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2008-May
OriginalsprogEngelsk
TidsskriftHIV Medicine
Vol/bind9
Udgave nummer5
Sider (fra-til)300-306
Antal sider6
ISSN1464-2662
DOI
StatusUdgivet - 1. maj 2008

Fingeraftryk

Virus Diseases
Coinfection
Hepatitis B virus
Cohort Studies
HIV
Hepatitis B e Antigens
Chronic Hepatitis B
Confidence Intervals
Viral Load
HIV-1
Acquired Immunodeficiency Syndrome
Prospective Studies
Liver

Citer dette

Omland, L H ; Weis, N ; Skinhøj, P ; Laursen, Alex ; Christensen, Peer Brehm ; Nielsen, H I ; Møller, Axel ; Engsig, F ; Sørensen, Henrik Toft ; Obel, N. / Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals : a nationwide cohort study. I: HIV Medicine. 2008 ; Bind 9, Nr. 5. s. 300-306.
@article{276829d045e811dd9fbe000ea68e967b,
title = "Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study",
abstract = "BACKGROUND: The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infected patients on highly active antiretroviral treatment (HAART) is a matter of debate. The impact of HBeAg status is unknown. METHODS: This prospective cohort study included all adult Danish HIV-1 infected patients who started HAART between 1 January 1995 and 1 December 2006 (3180 patients). Patients were classified as chronic HBV-infected (6{\%}), HBV-negative (87{\%}) or HBV-unknown (7{\%}). HBV-positive patients were divided into HBeAg-positive or -negative (3.0 vs. 2.6{\%}). Study endpoints were viral load, CD4 cell count and mortality. RESULTS: HBV co-infection had no impact on response to HAART regarding viral suppression or immune recovery. HBV co-infection was associated with several outcomes: overall mortality [mortality rate ratio (MRR) 1.5; 95{\%} confidence interval (CI) 1.1-2.1], liver-related mortality (MRR 4.0; 95{\%} CI 1.6-9.9) and AIDS-related deaths (MRR 1.7; 95{\%} CI 1.0-3.0). The presence of HBeAg did not influence patients' response to HAART. CONCLUSIONS: In HIV patients, chronic HBV infection has no impact on response to HAART concerning viral load and increase in CD4 cell count. However, co-infected patients have an increased mortality compared to HIV-monoinfected patients.",
author = "Omland, {L H} and N Weis and P Skinh{\o}j and Alex Laursen and Christensen, {Peer Brehm} and Nielsen, {H I} and Axel M{\o}ller and F Engsig and S{\o}rensen, {Henrik Toft} and N Obel",
year = "2008",
month = "5",
day = "1",
doi = "10.1111/j.1468-1293.2008.00564.x",
language = "English",
volume = "9",
pages = "300--306",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "5",

}

Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals : a nationwide cohort study. / Omland, L H; Weis, N; Skinhøj, P; Laursen, Alex; Christensen, Peer Brehm; Nielsen, H I; Møller, Axel; Engsig, F; Sørensen, Henrik Toft; Obel, N.

I: HIV Medicine, Bind 9, Nr. 5, 01.05.2008, s. 300-306.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals

T2 - a nationwide cohort study

AU - Omland, L H

AU - Weis, N

AU - Skinhøj, P

AU - Laursen, Alex

AU - Christensen, Peer Brehm

AU - Nielsen, H I

AU - Møller, Axel

AU - Engsig, F

AU - Sørensen, Henrik Toft

AU - Obel, N

PY - 2008/5/1

Y1 - 2008/5/1

N2 - BACKGROUND: The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infected patients on highly active antiretroviral treatment (HAART) is a matter of debate. The impact of HBeAg status is unknown. METHODS: This prospective cohort study included all adult Danish HIV-1 infected patients who started HAART between 1 January 1995 and 1 December 2006 (3180 patients). Patients were classified as chronic HBV-infected (6%), HBV-negative (87%) or HBV-unknown (7%). HBV-positive patients were divided into HBeAg-positive or -negative (3.0 vs. 2.6%). Study endpoints were viral load, CD4 cell count and mortality. RESULTS: HBV co-infection had no impact on response to HAART regarding viral suppression or immune recovery. HBV co-infection was associated with several outcomes: overall mortality [mortality rate ratio (MRR) 1.5; 95% confidence interval (CI) 1.1-2.1], liver-related mortality (MRR 4.0; 95% CI 1.6-9.9) and AIDS-related deaths (MRR 1.7; 95% CI 1.0-3.0). The presence of HBeAg did not influence patients' response to HAART. CONCLUSIONS: In HIV patients, chronic HBV infection has no impact on response to HAART concerning viral load and increase in CD4 cell count. However, co-infected patients have an increased mortality compared to HIV-monoinfected patients.

AB - BACKGROUND: The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infected patients on highly active antiretroviral treatment (HAART) is a matter of debate. The impact of HBeAg status is unknown. METHODS: This prospective cohort study included all adult Danish HIV-1 infected patients who started HAART between 1 January 1995 and 1 December 2006 (3180 patients). Patients were classified as chronic HBV-infected (6%), HBV-negative (87%) or HBV-unknown (7%). HBV-positive patients were divided into HBeAg-positive or -negative (3.0 vs. 2.6%). Study endpoints were viral load, CD4 cell count and mortality. RESULTS: HBV co-infection had no impact on response to HAART regarding viral suppression or immune recovery. HBV co-infection was associated with several outcomes: overall mortality [mortality rate ratio (MRR) 1.5; 95% confidence interval (CI) 1.1-2.1], liver-related mortality (MRR 4.0; 95% CI 1.6-9.9) and AIDS-related deaths (MRR 1.7; 95% CI 1.0-3.0). The presence of HBeAg did not influence patients' response to HAART. CONCLUSIONS: In HIV patients, chronic HBV infection has no impact on response to HAART concerning viral load and increase in CD4 cell count. However, co-infected patients have an increased mortality compared to HIV-monoinfected patients.

U2 - 10.1111/j.1468-1293.2008.00564.x

DO - 10.1111/j.1468-1293.2008.00564.x

M3 - Journal article

VL - 9

SP - 300

EP - 306

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 5

ER -